Upfront Investment in Clinical Trials and Other Activities
First written in FY2017-Q1. 14 of 24 entries say "Restated". Latest entry: FY2023.
Stella Chemifa moved to the "Worse" side of this theme in 2021, the same year as the typical company in this theme.
The whole theme swung hardest in 2021: 5 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2023ReframedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, no results for this segment have been recorded since the current consolidated fiscal year.」
The company has shifted from recording BNCT drug sales and upfront investment as the Medical business of a consolidated subsidiary to not recording consolidated segment results following the change to an equity-method affiliate. - FY2023-Q3RestatedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, no results for this segment have been recorded since the first quarter of the current consolidated fiscal year. Revenue in the same period of the previous year was ¥84 million, and the operating loss was ¥511 million.」
Following the change in the scope of consolidation of STELLA PHARMA CORPORATION, the company continues not to record the consolidated results of the Medical business. - FY2023-Q2RestatedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, no results for this segment have been recorded since the first quarter of the current consolidated fiscal year. Revenue in the same period of the previous year was ¥69 million, and the operating loss was ¥332 million.」
Following the change in the scope of consolidation of STELLA PHARMA CORPORATION, the company continues not to record the consolidated results of the Medical business. - FY2023-Q1ReframedAnnual report
「Because STELLA PHARMA CORPORATION, which operates the Medical business, changed from a consolidated subsidiary to an equity-method affiliate, no results for this segment were recorded in the cumulative three-month period of the current consolidated fiscal year.」
Following the change of STELLA PHARMA CORPORATION from a consolidated subsidiary to an equity-method affiliate, the company has shifted from disclosing BNCT drug sales and upfront investment as part of the consolidated Medical business to not recording the Medical segment's quarterly results on a consolidated basis. - FY2022-Q3WorsenedAnnual report
「In the Medical business, the previous year's same period represented the initial shipment of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, following marketing approval, and shipments included inventory held by wholesalers. As a result, revenue was ¥84 million, down 45.7% year on year, and the operating loss was ¥511 million, compared with an operating loss of ¥482 million in the same period of the previous year.」
Sales of the boron-based BNCT drug are continuing, but revenue fell 45.7% year on year due to the reaction to the initial shipment in the same period of the previous year, and the operating loss widened from ¥482 million to ¥511 million. - FY2022-Q2WorsenedAnnual report
「In the Medical business, the previous year's same period represented the initial shipment of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, following marketing approval, and shipments included inventory held by wholesalers. As a result, revenue was ¥69 million, down 53.2% year on year, and the operating loss was ¥332 million, compared with an operating loss of ¥286 million in the same period of the previous year.」
Sales of the boron-based BNCT drug are continuing, but revenue fell 53.2% due to the reaction to the initial shipment in the same period of the previous year, and the operating loss widened from ¥286 million to ¥332 million. - FY2022-Q1WorsenedAnnual report
「In the Medical business, the previous year's same period represented the initial shipment of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, following marketing approval, and shipments included inventory held by wholesalers. As a result, revenue was ¥7 million, down 93.0% year on year, and the operating loss was ¥182 million, compared with an operating loss of ¥115 million in the same period of the previous year.」
Sales of the boron-based BNCT drug are continuing, but revenue fell 93.0% due to the reaction to the initial shipment in the same period of the previous year, and the operating loss widened. - FY2021RestatedAnnual report
「In the Medical business, sales of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, began for head and neck cancer and revenue was recognized. In addition, efforts to reduce expenses resulted in lower selling, general and administrative expenses. Revenue was ¥205 million, compared with no revenue in the previous fiscal year, and the operating loss was ¥644 million, compared with an operating loss of ¥1,035 million in the previous fiscal year.」
Sales and revenue recognition for the boron-based BNCT drug, as well as cost reductions, continued, and the operating loss narrowed from the previous fiscal year. - FY2021-Q3RestatedAnnual report
「In the Medical business, sales of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, began for head and neck cancer and revenue was recognized. In addition, efforts to reduce expenses resulted in lower selling, general and administrative expenses, and the operating loss narrowed to ¥482 million, compared with an operating loss of ¥768 million in the same period of the previous year.」
The disclosure continues to report sales and revenue recognition for the boron-based BNCT drug for head and neck cancer, as well as lower selling, general and administrative expenses due to cost reductions. The operating loss narrowed from ¥768 million in the same period of the previous year to ¥482 million. - FY2021-Q2RestatedAnnual report
「In the Medical business, sales of the boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, began for head and neck cancer and revenue was recognized. In addition, efforts to reduce expenses resulted in lower selling, general and administrative expenses, and the operating loss narrowed to ¥286 million, compared with an operating loss of ¥536 million in the same period of the previous year.」
The disclosure continues to report sales and revenue recognition for the boron-based BNCT drug for head and neck cancer, as well as lower selling, general and administrative expenses due to cost reductions and a narrower operating loss. - FY2021-Q1AdvancedAnnual report
「The boron-based drug for boron neutron capture therapy (BNCT), a cancer treatment, obtained marketing approval for the indication of unresectable locally advanced or locally recurrent head and neck cancer and was listed on the National Health Insurance drug price list, enabling sales to begin and revenue to be recognized. In addition, efforts to reduce expenses resulted in lower selling, general and administrative expenses, and the operating loss narrowed to ¥115 million, compared with an operating loss of ¥282 million in the same period of the previous year.」
The company has progressed from the stage of upfront investment in clinical trials and preparations for approval through the previous fiscal year to the stage of National Health Insurance drug price listing, commencement of sales and revenue recognition for the boron-based BNCT drug, while the operating loss has also narrowed. - FY2020AdvancedAnnual report
「STELLA PHARMA CORPORATION obtained marketing approval for a boron-based drug for boron neutron capture therapy (BNCT), indicated for unresectable locally advanced or locally recurrent head and neck cancer.」
The company has progressed from upfront investment in clinical trials and preparations for approval to the specific milestone of obtaining marketing approval for the boron-based BNCT drug. - FY2020-Q3RestatedAnnual report
「In the Medical business, upfront investment expenses for BNCT clinical trials and preparations for an application for marketing approval resulted in an operating loss of ¥768 million, compared with an operating loss of ¥766 million in the same period of the previous year.」
Upfront investment in BNCT clinical trials and preparations for an application for marketing approval is continuing, and the operating loss for the nine-month period was ¥768 million. - FY2020-Q2Explicit reference to preparations for the applicationAnnual report
「In the Medical business, increased upfront investment expenses for BNCT clinical trials and preparations for an application for marketing approval resulted in an operating loss of ¥536 million, compared with an operating loss of ¥505 million in the same period of the previous year.」
In addition to the existing BNCT clinical trials, the disclosure explicitly mentions upfront investment toward an application for marketing approval. It does not mention the completion of the application or the achievement of any other milestone. - FY2020-Q1RestatedAnnual report
「In the Medical business, upfront investment expenses, including the implementation of clinical trials for boron neutron capture therapy (BNCT), a next-generation cancer treatment, resulted in an operating loss of ¥282 million, compared with an operating loss of ¥243 million in the same period of the previous year.」
Upfront investment, including BNCT clinical trials and other activities, is continuing and has consequently resulted in an operating loss. - FY2019-Q3RestatedAnnual report
「In the Medical business, upfront investment expenses, including the implementation of clinical trials for boron neutron capture therapy (BNCT), a next-generation cancer treatment, resulted in an operating loss of ¥766 million, compared with an operating loss of ¥704 million in the same period of the previous year.」
Upfront investment, including the implementation of BNCT clinical trials and other activities, is continuing and has consequently resulted in an operating loss. - FY2019-Q2RestatedAnnual report
「In the Medical business, the company is advancing clinical trials of boron neutron capture therapy (BNCT), a next-generation cancer treatment. As a result of upfront investment expenses, including the implementation of Phase II clinical trials as part of the clinical trials, continuing from the previous consolidated fiscal year, the company recorded an operating loss of ¥505 million, compared with an operating loss of ¥440 million in the same period of the previous year.」
Upfront investment in BNCT clinical trials, particularly including Phase II clinical trials, is continuing. - FY2019-Q1AdvancedAnnual report
「In the Medical business, the company is advancing clinical trials of boron neutron capture therapy (BNCT), a next-generation cancer treatment. As a result of upfront investment expenses, including the implementation of Phase II clinical trials as part of the clinical trials, continuing from the previous consolidated fiscal year, the company recorded an operating loss of ¥243 million, compared with an operating loss of ¥210 million in the same period of the previous year.」
The disclosure specifically states that, in addition to the previous upfront investment in clinical trials and other activities, the company is conducting Phase II clinical trials as part of the BNCT clinical trial. - FY2018-Q3RestatedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥704 million, compared with an operating loss of ¥585 million in the same period of the previous year.」
The disclosure continues to explain that upfront investment in clinical trials and other activities is continuing and has consequently resulted in an operating loss. - FY2018-Q2RestatedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥440 million, compared with an operating loss of ¥385 million in the same period of the previous year.」
The disclosure continues to explain that upfront investment in clinical trials and other activities is continuing and has resulted in an operating loss. - FY2018-Q1RestatedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥210 million, compared with an operating loss of ¥209 million in the same period of the previous year.」
The disclosure states that upfront investment in clinical trials and other activities continued and that an operating loss was recorded in the three-month period ended in the first quarter. - FY2017-Q3RestatedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥585 million, compared with an operating loss of ¥469 million in the same period of the previous year.」
The company explains that it continues to make upfront investments in clinical trials and other activities, resulting in an operating loss. - FY2017-Q2RestatedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥385 million, compared with an operating loss of ¥258 million in the same period of the previous year.」
The disclosure states that upfront investment in clinical trials and other activities continued and that an operating loss was recorded in the six-month period ended in the second quarter. - FY2017-Q1First statedAnnual report
「In the Medical business, upfront investment expenses for clinical trials and other activities continued from the previous fiscal year, resulting in an operating loss of ¥209 million, compared with an operating loss of ¥138 million in the same period of the previous year.」
The disclosure states that upfront investment in clinical trials and other activities continues in the Medical business and has resulted in an operating loss.